PMID- 27696192
OWN - NLM
STAT- MEDLINE
DCOM- 20170426
LR  - 20220331
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 105
IP  - 3
DP  - 2017 Mar
TI  - Fulminant type I diabetes mellitus associated with nivolumab in a patient with 
      relapsed classical Hodgkin lymphoma.
PG  - 383-386
LID - 10.1007/s12185-016-2101-4 [doi]
AB  - We report the case of a patient with relapsed classical Hodgkin lymphoma who 
      developed fulminant type I diabetes mellitus as a severe adverse event of 
      treatment with the anti-programmed cell death-1 (PD-1) antibody, nivolumab. On 
      the first day of the sixth cycle, the blood glucose level was markedly elevated 
      (375 mg/dL). Although neither ketoacidosis nor ketonuria was detected, the 
      markedly acute onset of the hyperglycemia was consistent with the typical 
      clinical course of fulminant type I diabetes mellitus, and this diagnosis was 
      supported by clinical data. All autoantibodies associated with type I diabetes 
      mellitus were negative. The endogenous insulin secretion ceased completely within 
      2 weeks. After the blood glucose level was brought under control, nivolumab was 
      resumed and continued without other major adverse events. Human leukocyte antigen 
      (HLA) analysis revealed that the patient carried the HLA-B*4002 haplotype, a 
      susceptibility allele for this type of diabetes mellitus. This case suggests that 
      fulminant type I diabetes mellitus may be triggered by nivolumab in patients with 
      a genetic background associated with the condition, warranting careful future 
      consideration of this particular adverse event.
FAU - Munakata, Wataru
AU  - Munakata W
AUID- ORCID: 0000-0002-4679-0656
AD  - Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, 
      Chuo-ku, Tokyo, 104-0045, Japan. wmunakat@ncc.go.jp.
FAU - Ohashi, Ken
AU  - Ohashi K
AD  - Department of General Internal Medicine, National Cancer Center Hospital, 5-1-1 
      Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Yamauchi, Nobuhiko
AU  - Yamauchi N
AD  - Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, 
      Chuo-ku, Tokyo, 104-0045, Japan.
FAU - Tobinai, Kensei
AU  - Tobinai K
AD  - Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, 
      Chuo-ku, Tokyo, 104-0045, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20161001
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (HLA-B Antigens)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/*adverse effects/therapeutic use
MH  - Diabetes Mellitus, Type 1/*chemically induced/diagnosis/genetics
MH  - Genetic Predisposition to Disease
MH  - HLA-B Antigens/analysis/genetics
MH  - Hodgkin Disease/*complications/drug therapy
MH  - Humans
MH  - Male
MH  - Nivolumab
MH  - Recurrence
OTO - NOTNLM
OT  - Anti-PD-1 antibody
OT  - Fulminant type I diabetes mellitus
OT  - Immune-related adverse events
OT  - Nivolumab
EDAT- 2016/10/04 06:00
MHDA- 2017/04/27 06:00
CRDT- 2016/10/04 06:00
PHST- 2016/07/11 00:00 [received]
PHST- 2016/09/26 00:00 [accepted]
PHST- 2016/09/20 00:00 [revised]
PHST- 2016/10/04 06:00 [pubmed]
PHST- 2017/04/27 06:00 [medline]
PHST- 2016/10/04 06:00 [entrez]
AID - 10.1007/s12185-016-2101-4 [pii]
AID - 10.1007/s12185-016-2101-4 [doi]
PST - ppublish
SO  - Int J Hematol. 2017 Mar;105(3):383-386. doi: 10.1007/s12185-016-2101-4. Epub 2016 
      Oct 1.